
Peter Georgantopoulos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4365412/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncology, The, 2014, 15, e594-e605.	10.7	99
2	Generic oncology drugs: are they all safe?. Lancet Oncology, The, 2016, 17, e493-e501.	10.7	33
3	Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network. Journal of Community and Supportive Oncology, 2016, 14, 54-65.	0.1	32
4	Progressive multiâ€focal leucoencephalopathy among ibrutinibâ€treated persons with chronic lymphocytic leukaemia. British Journal of Haematology, 2018, 180, 301-304.	2.5	16
5	Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncology, 2016, 2, 134.	7.1	15
6	Patient- and area-level predictors of prostate cancer among South Carolina veterans: a spatial analysis. Cancer Causes and Control, 2020, 31, 209-220.	1.8	6
7	Deficient ADAMTS13 Activity in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura (TTP) in Populations From Japan in 2012: Validation of Findings Initially Reported in the United States in 1998 and 2000 Blood, 2012, 120, 2203-2203.	1.4	3
8	Rituximab is associated with increased risk of Progressive Multifocal Leukoencephalopathy developing among non-HIV-infected Veterans with Chronic Lymphocytic Leukemia Journal of Clinical Oncology, 2015, 33, e18033-e18033.	1.6	2
9	Rituximab-Associated Progressive Multifocal Leukoencephalopathy (PML) in HIV-Negative Patients: An Updated Report of 231 Confirmed Cases from the Southern Network on Adverse Reactions (SONAR)/Washington University Collaboration (2000-2012). Blood, 2014, 124, 4456-4456.	1.4	2
10	Japanese regulatory authority's perspective on biosimilars – Authors' reply. Lancet Oncology, The, 2015, 16, e102.	10.7	0
11	A spatial assessment of prostate cancer mortality-to-incidence ratios among South Carolina veterans: 1999–2015. Annals of Epidemiology, 2021, 59, 24-32.	1.9	0
12	The "Double Whammy― Effects of erythropoiesis stimulating agents (ESAs) when administered to patients with both end stage renal disease (ESRD) and cancer Journal of Clinical Oncology, 2015, 33, e17623-e17623.	1.6	0
13	Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome: A proactive pharmacovigilance program (SONAR) and comparative safety efforts of the Food and Drug Administration Journal of Clinical Oncology, 2015, 33, e18035-e18035.	1.6	0
14	Unexpected pegensatide failure: Plea for an extension of an effective FDA early warning system Journal of Clinical Oncology, 2015, 33, e17625-e17625.	1.6	0